Lineage Cell Therapeutics 2024 Corporate Presentation

Lineage Cell Therapeutics presents its regenerative medicine platform focused on directed differentiation and transplant of allogeneic cells. The company highlights two product candidates in active clinical trials, including OpRegen with a validated partnership worth up to $1.3B with Roche/Genentech, and demonstrates capability across five cell types in development addressing multi-billion dollar markets.